Department of Dermatology, University of Lübeck, Lübeck, Germany.
Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.
PLoS One. 2022 Sep 27;17(9):e0275293. doi: 10.1371/journal.pone.0275293. eCollection 2022.
Psoriasis is a chronic immune-mediated inflammatory disease. Beyond the physical dimensions, the disease has an extensive emotional and psychosocial effect on patients, influencing their quality of life, social life and interpersonal relationships. Thus patient-reported outcomes are a crucial instrument for the evaluation of disease burden. Navigating life in times of the COVID-19 pandemic is challenging, especially for persons suffering from chronic diseases. We here analyzed the impact of lockdown restrictions on psoriasis patients.
To compare the Dermatology Life Quality Index (DLQI) before and during the COVID-19 pandemic of patients with psoriasis.
Retrospective longitudinal analysis in adult patients with moderate to severe psoriasis undergoing biologic treatment between January 2020 and January 2021. DLQI, patient demographics, Psoriasis Area and Severity Index (PASI), and recent biologic treatment were recorded.
103 patients were identified, of whom 19 had additional psoriatic arthritis. Female (n = 29) and male (n = 74) patients were distributed 1 to 3. Median age of patients was 54 years (range 18-85). All patients received biologic systemic treatment: anti-IL-23 (n = 39), anti-IL-17A (n = 30), anti-IL-12/23 (n = 25), or anti-TNFα (n = 9). Comparing DLQI scores before the COVID-19 pandemic and under lockdown restriction showed improved DLQI scores over time. Further analysis displayed that patients mostly ticked "not relevant" on social activities during lockdown. Thus, the DLQI scores may be artificial improved and may not really reflect the actual disease burden.
Psoriasis patients showed a contrary improvement of life quality despite harsh COVID-19 lockdown suggesting that DLQI should be modified when social life is restricted.
银屑病是一种慢性免疫介导的炎症性疾病。除了身体上的影响，疾病还会给患者带来广泛的情绪和心理社会影响，影响他们的生活质量、社交生活和人际关系。因此，患者报告的结果是评估疾病负担的重要工具。在 COVID-19 大流行期间，生活变得充满挑战，尤其是对于患有慢性疾病的人。我们在此分析了封锁限制对银屑病患者的影响。
比较银屑病患者在 COVID-19 大流行前后的皮肤病生活质量指数（DLQI）。
回顾性纵向分析 2020 年 1 月至 2021 年 1 月期间接受生物治疗的中重度银屑病成年患者。记录 DLQI、患者人口统计学、银屑病面积和严重程度指数（PASI）和最近的生物治疗情况。
共确定了 103 名患者，其中 19 名患有额外的银屑病关节炎。女性（n = 29）和男性（n = 74）患者分别为 1 至 3 名。患者的中位年龄为 54 岁（范围 18-85 岁）。所有患者均接受生物系统治疗：抗 IL-23（n = 39）、抗 IL-17A（n = 30）、抗 IL-12/23（n = 25）或抗 TNFα（n = 9）。与 COVID-19 大流行前和封锁期间的 DLQI 评分相比，DLQI 评分随时间推移有所改善。进一步分析显示，患者在封锁期间在社交活动上大多勾选“不相关”。因此，DLQI 评分可能是人为改善的，可能并不能真正反映实际的疾病负担。
尽管 COVID-19 封锁严格，但银屑病患者的生活质量显示出相反的改善，这表明当社交生活受到限制时，应修改 DLQI。
